Publication | Closed Access
A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor b
28
Citations
44
References
2019
Year
Hiv-1 Latency-reversing AgentHuman RetrovirusNovel Bromodomain InhibitorImmunologyAntiviral Drug DevelopmentAntiviral TherapyAntiviral ResponseHivMedicineCell Biology
| Year | Citations | |
|---|---|---|
Page 1
Page 1